RVMD
The table below shows Revolution Medicines, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $343.97M | $262.51M | $224.13M | $205.75M | $151.75M | $134.93M |
Revolution Medicines, Inc. reported annual revenue of $0.00 for fiscal year 2025. Over the 8 fiscal years shown, annual revenue declined from $20.16M (FY 2018) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $101.25M |
| $52.76M |
| $40.58M |
| $35.01M |
| $23.96M |
| $21.71M |
| Operating income | -$445.22M | -$315.27M | -$264.71M | -$240.76M | -$175.71M | -$156.64M |
| Income tax | - | - | - | - | $0.00 | $0.00 |
| Net income | -$453.82M | -$305.21M | -$247.79M | -$213.42M | -$156.29M | -$133.23M |
| EPS (diluted) | -$2.29 | -$1.61 | -$1.31 | -$1.13 | -$0.94 | -$0.81 |